It appears science may have found the Covid-19 pandemic’s off-ramp.
Two vaccines developed with stunning speed — and showing remarkable initial efficacy — are poised to be approved for emergency use in the United States in December. A number of other vaccines are expected to follow.
Vaccines that prevent symptomatic Covid infection in roughly 95% of people vaccinated — as the data from clinical trials of the Pfizer-BioNTech and Moderna vaccines suggest — should, over time, help the country and the world return to a life where we can travel without quarantining; where sporting events can be played before live audiences, not cardboard cutouts; and where snowstorms are the only reasons school gets canceled.
But if we’re not careful, we could fail to take full advantage of the opportunity scientists and governments, pharmaceutical companies and philanthropic foundations have created for us. Read more >>